샘플 요청 목록

 카트 문의
시장보고서
상품코드
1986374

CAUTI 예방용 비뇨기과 제품 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

CAUTI Prevention Urology Products Market Size, Share & Trends Analysis Report By Product (Preventive Drainage Devices (Primary Prevention), Sterile Circuit & Maintenance Systems), By Application, By End-Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 125 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,005,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,518,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,545,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

CAUTI 예방용 비뇨기과 제품의 시장 요약

세계의 CAUTI 예방용 비뇨기과 제품 시장 규모는 2025년에 34억 3,000만 달러로 평가되며, 2033년까지 60억 5,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 7.35%로 성장할 전망입니다.

이 시장은 카테터 관련 요로감염(CAUTI) 발생률의 증가와 의료 현장의 감염 관리에 대한 인식이 높아짐에 따라 성장하고 있습니다.

엄격한 규제 지침과 병원내 감염을 줄이기 위한 병원의 노력으로 항균 및 안전성이 강화된 비뇨기과 제품의 채택이 가속화되고 있습니다. 입원율 증가, 고령화, 급성기 및 장기 치료에서 요도 카테터 사용의 증가는 시장 성장을 더욱 촉진하고 있습니다. CAUTI 및 기타 병원내 감염 발생률의 증가는 CAUTI 예방 비뇨기과 제품 시장의 주요 촉진요인으로 작용하고 있습니다.

환자 안전에 대한 인식이 높아진 데다 장기 입원이 초래하는 임상적, 경제적 영향으로 인해 의료 서비스 제공자는 감염 예방을 최우선 과제로 삼아야 합니다. 이로 인해 감염 위험을 줄이기 위해 설계된 항균 카테터, 폐쇄형 배액 시스템, 카테터 관리 솔루션 등 첨단 비뇨기과 제품에 대한 수요가 가속화되고 있습니다. 미국 의료안전네트워크(NHSN)에 따르면 성인 입원 환자의 약 12%-16%가 입원 기간 중 어느 시점에 카테터를 사용하고 있다고 합니다. 카테터 삽입 기간이 하루 늘어날 때마다 환자가 카테터 관련 요로감염(CAUTI)에 걸릴 위험은 3%-7% 증가합니다.

CAUTI 사례가 증가함에 따라 의료 시설은 환자 이환율 증가, 입원 기간 연장 및 치료 비용 증가에 직면하고 있습니다. 이러한 위험을 줄이기 위해 병원과 의료진은 항균 카테터, 밀폐형 배액 시스템, 카테터 고정 장치 및 대체 방광 관리 솔루션과 같은 감염 예방을 위한 비뇨기과 제품을 채택하고 있습니다. 감염률 감소와 임상 가이드라인 준수에 대한 요구가 높아지면서 CAUTI 예방 시장의 수요와 혁신이 직접적으로 촉진되고 있습니다.

요실금은 병원, 요양시설, 재가 요양시설에서 카테터 사용을 증가시켜 카테터 관련 요로감염의 위험을 증가시킴으로써 CAUTI 예방 비뇨기과 제품 시장을 크게 견인하고 있습니다. 이로 인한 임상적 합병증, 입원 기간의 장기화, 의료비 증가로 인해 의료진은 항균 카테터, 밀폐형 배액 시스템, 비침습적 방광 관리 대안과 같은 CAUTI 예방 전략을 도입하여 치료 결과를 개선하고 감염률을 낮추기 위해 노력해야 합니다. 비뇨기과학재단(Urology Foundation)에 따르면 현재 영국에서는 약 500만 명이 과민성 방광을 앓고 있으며, 이 숫자는 2035년까지 700만 명 이상으로 늘어날 것으로 예측됩니다.

자주 묻는 질문

  • CAUTI 예방용 비뇨기과 제품 시장 규모는 어떻게 예측되나요?
  • CAUTI 예방용 비뇨기과 제품 시장의 성장 요인은 무엇인가요?
  • CAUTI 예방을 위한 비뇨기과 제품의 수요가 증가하는 이유는 무엇인가요?
  • CAUTI 예방용 비뇨기과 제품의 주요 종류는 무엇인가요?
  • 요실금이 CAUTI 예방용 비뇨기과 제품 시장에 미치는 영향은 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 CAUTI 예방용 비뇨기과 제품의 시장 요인, 동향 및 범위

제4장 CAUTI 예방 비뇨기과 제품 시장 : 제품별 추정·동향 분석

제5장 CAUTI 예방 비뇨기과 제품 시장 : 용도별 추정·동향 분석

제6장 CAUTI 예방 비뇨기과 제품별 시장 : 최종 용도별 추정·동향 분석

제7장 CAUTI 예방 비뇨기과 제품 시장 : 제품, 용도, 최종 용도별 지역별 추정·동향 분석

제8장 경쟁 구도

KSA 26.04.28

CAUTI Prevention Urology Products Market Summary

The global CAUTI prevention urology products market size was valued at USD 3.43 billion in 2025 and is projected to reach USD 6.05 billion by 2033, growing at a CAGR of 7.35% from 2026 to 2033. The market is driven by the rising incidence of catheter-associated urinary tract infections and increasing awareness of infection control in healthcare settings.

Strict regulatory guidelines and hospital initiatives to reduce hospital-acquired infections are accelerating the adoption of antimicrobial and safety-enhanced urology products. Growing hospitalization rates, an aging population, and expanded use of urinary catheters in acute and long-term care further support market growth. The rising incidence of CAUTIs and other hospital-acquired infections is a key driver of the CAUTI prevention urology products market.

Increased awareness of patient safety, coupled with the clinical and financial impact of prolonged hospital stays, is pushing healthcare providers to prioritize infection prevention. This has accelerated demand for advanced urology products such as antimicrobial catheters, closed drainage systems, and catheter management solutions designed to reduce infection risk. According to the National Healthcare Safety Network (NHSN), about 12%-16% of adult hospital patients use an indwelling urinary catheter at some point during their hospital stay. Each additional day the catheter remains in place increases the patient's risk of developing a catheter-associated urinary tract infection (CAUTI) by 3%-7%.

As CAUTI cases rise, healthcare facilities face higher patient morbidity, longer hospital stays, and increased treatment costs. To mitigate these risks, hospitals and care providers adopt infection-prevention urology products such as antimicrobial catheters, closed drainage systems, catheter securement devices, and alternative bladder management solutions. The growing need to reduce infection rates and comply with clinical guidelines directly fuels the demand and innovation in the CAUTI prevention market.

Urinary incontinence significantly drives the CAUTI prevention urology products market by increasing catheter use across hospitals, care homes, and home care settings, thereby increasing the risk of catheter-associated urinary tract infections. The resulting clinical complications, longer hospital stays, and increased healthcare costs are prompting providers to adopt CAUTI prevention strategies, such as antimicrobial catheters, closed drainage systems, and non-invasive bladder management alternatives, to improve outcomes and reduce infection rates. According to the Urology Foundation, an estimated 5 million people in England currently live with an overactive bladder, and this number is projected to increase to more than 7 million by 2035.

Global CAUTI Prevention Urology Products Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global CAUTI prevention urology products market report on the basis of product, application, end use and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Preventive Drainage Devices (Primary Prevention)
    • Intermittent (Single-Use) Catheters
    • Antibacterial/Antimicrobial-Coated
    • Compact/Travel Intermittent
    • External (Non-Invasive) Collection Systems
    • Indwelling (Foley) Catheters
    • Silver-Alloy Coated Foley
    • Silicone-Only Foley
    • Drug-Eluting Catheters
  • Sterile Circuit & Maintenance Systems (Mechanical Prevention)
    • Closed Drainage Bags
    • Anti-Reflux Systems
    • Urine Meters
    • Catheter Stabilization/Securement Devices
    • Needleless Sampling Ports
  • Procedural Support & "Insertion Bundles" (Aseptic Prevention)
    • Pre-Packaged Aseptic Trays
    • Bladder Scanners (Portable Ultrasound)
    • Sterile Lubricant & Cleansing Solutions
  • Application Outlook (Revenue, USD Million; 2021 - 2033)
  • Urinary Incontinence Management
  • Acute Surgical/Perioperative Care
  • Benign Prostatic Hyperplasia (BPH) and Obstructive Urology
  • Neurogenic Bladder & Spinal Cord Injury (SCI)
  • End Use Outlook (Revenue, USD Million; 2021 - 2033)
  • Hospitals
  • Long Term Care Facilities
  • Home Care Setting
  • Ambulatory Surgical Centers (ASCs)
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. CAUTI Prevention Urology Products Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing use of urinary catheters in healthcare
      • 3.2.1.2. Greater focus on infection prevention in healthcare
      • 3.2.1.3. Innovation in product design and material
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of advanced catheters
      • 3.2.2.2. Lack of awareness in certain settings
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Growth in home healthcare adoption
      • 3.2.3.2. Rising awareness of infection prevention
      • 3.2.3.3. Emerging markets and developing regions
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Reimbursement challenges
  • 3.3. CAUTI Prevention Urology Products Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal landscape

Chapter 4. CAUTI Prevention Urology Products Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global CAUTI Prevention Urology Products Market: Product Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Global CAUTI Prevention Urology Products Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Preventive Drainage Devices (Primary Prevention)
    • 4.4.1. Preventive drainage devices (primary prevention) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Intermittent (single-use) catheters
      • 4.4.2.1. Intermittent (single-use) catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Antibacterial/antimicrobial-coated
        • 4.4.2.2.1. Antibacterial/antimicrobial-Coated market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Compact/travel intermittent
        • 4.4.2.3.1. Compact/travel intermittent market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. External (non-invasive) collection systems
      • 4.4.3.1. External (non-invasive) collection systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Indwelling (foley) catheters
      • 4.4.4.1. Indwelling (foley) catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.2. Silver-alloy coated foley
        • 4.4.4.2.1. Silver-alloy coated foley market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.3. Silicone-only foley
        • 4.4.4.3.1. Silicone-only foley market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.4. Drug-eluting catheters
        • 4.4.4.4.1. Drug-eluting catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Sterile circuit & maintenance systems (mechanical prevention)
    • 4.5.1. Sterile circuit & maintenance systems (mechanical prevention) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Closed drainage bags
      • 4.5.2.1. Closed drainage bags market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.2. Anti-reflux systems
        • 4.5.2.2.1. Anti-reflux systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.5.2.3. Urine meters
        • 4.5.2.3.1. Urine meters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Catheter stabilization/securement devices
      • 4.5.3.1. Catheter stabilization/securement devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Needleless Sampling Ports
      • 4.5.4.1. Needleless sampling ports market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Procedural Support & "Insertion Bundles" (Aseptic Prevention)
    • 4.6.1. Procedural support & "insertion bundles" (aseptic prevention) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Pre-packaged aseptic trays
      • 4.6.2.1. Pre-packaged aseptic trays market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Bladder Scanners (Portable Ultrasound)
      • 4.6.3.1. Bladder scanners (portable ultrasound) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Sterile lubricant & cleansing solutions
      • 4.6.4.1. Sterile lubricant & cleansing solutions market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. CAUTI Prevention Urology Products Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global CAUTI Prevention Urology Products Market: Application Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Global CAUTI Prevention Urology Products Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
  • 5.4. Urinary Incontinence Management
    • 5.4.1. Urinary incontinence management market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Acute Surgical/Perioperative Care
    • 5.5.1. Acute surgical/perioperative care market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Benign Prostatic Hyperplasia (BPH) and Obstructive Urology
    • 5.6.1. Benign prostatic hyperplasia (BPH) and obstructive urology market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Neurogenic Bladder & Spinal Cord Injury (SCI)
    • 5.7.1. Neurogenic bladder & spinal cord injury (SCI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. CAUTI Prevention Urology Products Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global CAUTI Prevention Urology Products Market: End use Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Global CAUTI Prevention Urology Products Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Long Term Care Facilities
    • 6.5.1. Long term care facilities market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Home Care Setting
    • 6.6.1. Home care setting market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Ambulatory surgical centers (ASCs)
    • 6.7.1. Ambulatory surgical centers (ASCs) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. CAUTI Prevention Urology Products Market: Regional Estimates & Trend Analysis by Product, Application and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size and Trend Analysis, 2021 to 2033
  • 7.3. North America
    • 7.3.1. North America CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. Reimbursement scenario
      • 7.3.2.5. U.S. CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Reimbursement scenario
      • 7.3.3.5. Canada CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Reimbursement scenario
      • 7.3.4.5. Mexico CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement scenario
      • 7.4.2.5. UK CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement scenario
      • 7.4.3.5. Germany CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement scenario
      • 7.4.4.5. France CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Reimbursement scenario
      • 7.4.5.5. Italy CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Reimbursement scenario
      • 7.4.6.5. Spain CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Reimbursement scenario
      • 7.4.7.5. Sweden CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Reimbursement scenario
      • 7.4.8.5. Denmark CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Reimbursement scenario
      • 7.4.9.5. Norway CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. China CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. Japan CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. India CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement scenario
      • 7.5.5.5. South Korea CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement scenario
      • 7.5.6.5. Australia CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Reimbursement scenario
      • 7.5.7.5. Thailand CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Brazil CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement scenario
      • 7.6.3.5. Argentina CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Middle East and Africa
    • 7.7.1. Middle East and Africa CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. South Africa CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. Saudi Arabia CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. UAE CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement scenario
      • 7.7.5.5. Kuwait CAUTI prevention urology products market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2025
  • 8.4. Company Heat Map Analysis
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research And Development
    • 8.5.6. Company Profiles
    • 8.5.7. BD
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. B. Braun SE
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Coloplast
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Teleflex Incorporated
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Cook Medical
      • 8.5.11.1. Company overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Medtronic
      • 8.5.12.1. Company overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. Hollister Incorporated
      • 8.5.13.1. Company overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic initiatives
    • 8.5.14. ConvaTec Group PLC
      • 8.5.14.1. Company overview
      • 8.5.14.2. Financial performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic initiatives
    • 8.5.15. Boston Scientific Corporation
      • 8.5.15.1. Company overview
      • 8.5.15.2. Financial performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic initiatives
    • 8.5.16. Cardinal Health
      • 8.5.16.1. Company overview
      • 8.5.16.2. Financial performance
      • 8.5.16.3. Product Benchmarking
      • 8.5.16.4. Strategic initiatives
    • 8.5.17. Merit Medical
      • 8.5.17.1. Company overview
      • 8.5.17.2. Financial performance
      • 8.5.17.3. Product Benchmarking
      • 8.5.17.4. Strategic initiatives
    • 8.5.18. Medline Industries, LP.
      • 8.5.18.1. Company overview
      • 8.5.18.2. Financial performance
      • 8.5.18.3. Product Benchmarking
      • 8.5.18.4. Strategic initiatives
    • 8.5.19. Poiesis Medical LLC
      • 8.5.19.1. Company overview
      • 8.5.19.2. Financial performance
      • 8.5.19.3. Product Benchmarking
      • 8.5.19.4. Strategic initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기